SCHEMBL10098573

SCHEMBL10098573

Clc1ccc2c(c1)-n1c(nnc1-c1ccccc1)CCN2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.50
CYP17A1 P05093 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP19A1 P11511 1/20 0.45
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
HPGD P15428 4/20 0.40
LMNA P02545 1/20 0.40
GABRA1 P14867 1/20 0.40
CNR1 P21554 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
OPRK1 P41145 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40
TSHR P16473 1/20 0.40
AVPR1A P37288 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1809261 0.92 BRD4 (0.46) BRD4CYP17A1CYP3A4CYP19A1CYP11B1
SCHEMBL316222 0.84 BRD4 (0.69) BRD4CYP17A1CYP3A4CYP19A1CYP11B1
SCHEMBL313644 0.78 BRD4 (0.43) BRD4CYP17A1CYP3A4CYP19A1CYP11B1
SCHEMBL314426 0.76 BRD4 (0.48) BRD4TSHRAVPR1ANPC1SMN1; SMN2
SCHEMBL314704 0.76 BRD4 (0.57) BRD4CYP17A1CYP3A4CYP19A1CYP11B1
SCHEMBL314003 0.75 BRD4 (0.43) BRD4CNR1GLAMEN1ALDH1A1
SCHEMBL313656 0.75 HSD11B1 (0.41) BRD4HPGDLMNAGABRA1CNR1
SCHEMBL313657 0.75 HSD11B1 (0.41) BRD4HPGDLMNAGABRA1CNR1
SCHEMBL313658 0.75 HSD11B1 (0.41) BRD4HPGDLMNAGABRA1CNR1
SCHEMBL12841365 0.71 TSHR (0.62) CYP17A1CYP3A4CYP19A1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
WO-2007079820-A1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 BRD4 808/4885CYP17A1 1362/4885CYP3A4 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.